

**Date: May 28, 2025**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir,

**Sub: Press Release to the Analysts/Investors**

We refer to the audited financial results for the fourth quarter and financial year ended on March 31, 2025, submitted to you today i.e., on May 28, 2025. We are now enclosing the press release to the Analysts/Investors.

This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

**For GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**



**REGISTERED OFFICE**

Granules India Limited  
CIN: L24110TG1991PLC012471  
15<sup>th</sup> Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India  
Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

[www.granulesindia.com](http://www.granulesindia.com)

**Q4FY25 Revenue from operations at INR 11,974 Mn up 2% YoY, EBITDA at INR 2,524 Mn down 1% YoY, PAT at INR 1,520 Mn up 17% YoY.**

**Hyderabad, India, May 28, 2025:** Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended March 31, 2025.

### Financial Summary (All numbers in INR Mn.)

QUARTERLY CONSOLIDATED FINANCIALS	Q4FY25	Q3FY25	Growth (QoQ)	Q4FY24	Growth (YoY)
Revenue from Operations	11,974	11,377	5%	11,758	2%
EBITDA	2,524	2,303	10%	2,557	(1%)
EBITDA %	21%	20%		22%	
PAT	1,520	1,176	29%	1,296	17%
PAT %	13%	10%		11%	

  

ANNUAL CONSOLIDATED FINANCIALS	FY25	FY24	Growth (YoY)
Revenue from Operations	44,816	45,064	(1%)
EBITDA	9,452	8,560	10%
EBITDA %	21%	19%	
PAT	5,015	4,053	24%
Net Profit Margin	11%	9%	

### Financial and Business Summary for Q4FY25

- Revenue from Operations of Q4FY25 stood at INR 11,974 mn, a growth of 2% YoY, Sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility with ongoing US FDA remediation activities. Revenue share from the North America increased to 79% in Q4 FY25 as compared to 70% in Q4 FY24.
- Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 12%, 10%, and 77% of revenue from operations respectively for Q4FY25.
- ROCE is at 16.6% as compared to 16.5% YoY.
- Net debt stood at INR 7,061 mn, a reduction of INR 1,360 mn and Net debt to EBITDA at 0.75x

**Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said,** “We are pleased to report a resilient bottom line and cash flow performance this year, despite sales remaining steady. This was achieved with a profitable Formulations growth of 18%, even though we proactively paused Gagillapur’s production operations in Sep-24 for more than a month to re-assess the risks and undertake necessary USFDA remediation activities. Productivity of Gagillapur facility has been lower in H2 FY25 with ongoing remediation activities. Our strong financial performance reflects the success of our strategic initiatives, particularly our focus on enhancing our product mix by prioritizing high-margin offerings and expanding our portfolio of non-legacy molecules. This reflects the strength and adaptability of our business model, and our unwavering commitment”.

### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

### **Safe Harbor**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*

<b>Contacts:</b>	
<b>Granules IR Desk</b> investorrelations@granulesindia.com	<b>Chaitanya Tummala</b> Company Secretary chaitanya.tummala@granulesindia.com